Clinical Trial Results: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy, safety, PK/PD, and immunogenicity of Ravulizumab in Chinese adults with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Status: COMPLETED | Results posted: 2026-06-05